About
Technology
Issues
FAQ
Links
Official Page
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.